RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.
about
A new insight into viral proteins as Immunomodulatory therapeutic agents: KSHV vOX2 a homolog of human CD200 as a potent anti-inflammatory proteinProstate cancer relevant antigens and enzymes for targeted drug deliveryA heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumorsRGD-Binding Integrins in Head and Neck Cancers.To Target or Not to Target: Active vs. Passive Tumor Homing of Filamentous Nanoparticles Based on Potato virus XThe Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter NanorodsPeptides used in the delivery of small noncoding RNA.miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.Degradable Polyethylenimine-Based Gene Carriers for Cancer Therapy.Integrins and Exosomes, a Dangerous Liaison in Cancer Progression.Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αV β3.ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy.Clinical study of 99mTc-3P-RGD2 peptide imaging in osteolytic bone metastasis.Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin.Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy.Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.pH-Switch Nanoprecipitation of Polymeric Nanoparticles for Multimodal Cancer Targeting and Intracellular Triggered Delivery of Doxorubicin.
P2860
Q26751623-1EEDF865-79E4-4515-836A-1CEEA54EB21AQ27013843-065AE269-A99A-4E80-A353-0A8BFB240FC4Q33616878-892EE7BD-3D2A-49AC-B694-6CAFD1038108Q33832735-DFC43C65-0113-485C-927D-597AFD43AC98Q35967955-A560F237-88A6-4C3B-9005-5405109186EBQ37068238-5DC2DA9F-CA5D-433D-B610-ABFB573C969AQ38243361-E2640E2D-A5D3-4820-B842-93FDFCE09772Q38512093-BA83570D-8A6F-4267-AFD0-2793025F3BA2Q39177170-7ECCE212-1449-4D5C-A59C-49E7DC7A9655Q41552575-E2FF2D1D-0E9C-457D-A304-8BB73A86C735Q42801541-B55FC40E-DF7B-4A3E-A6D0-A5E5FC7296C2Q43264652-7131E891-B55B-4476-B2AF-1BA1BEDB162CQ47171640-9131C3EE-F7C7-4762-B2F8-7B0050B06C4DQ47579071-4A3A0A41-20A7-4EFE-B44C-8D14E840E1D2Q48244235-1D4A9262-2A9C-47A0-9C5B-398EEDD2E5F9Q52653896-3BC80622-844A-4028-A42D-4CEC9E2720FAQ53091050-F815951B-911D-4DB0-90BA-C9470B65C4F1
P2860
RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
RGD-Binding Integrins in Prost ...... pects against Bone Metastasis.
@en
type
label
RGD-Binding Integrins in Prost ...... pects against Bone Metastasis.
@en
prefLabel
RGD-Binding Integrins in Prost ...... pects against Bone Metastasis.
@en
P2093
P2860
P356
P1433
P1476
RGD-Binding Integrins in Prost ...... spects against Bone Metastasis
@en
P2093
Andrew Gordon
Laurence H Patterson
Mark Sutherland
P2860
P304
P356
10.3390/CANCERS4041106
P577
2012-10-26T00:00:00Z